The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.
The method, called jagged end analysis by sequencing and developed by a team in Hong Kong, relies on DNA end repair with methylated or unmethylated cytosine.
